Developer docs
API playgroundTry for free, no card

Search company profiles

Deverra Therapeutics

Full company profile

uuid0000t6h

Namestring
Deverra Therapeutics
Legal namestring
Deverra Therapeutics, Inc.
Websiteurl
deverratx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Deverra Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered in Seattle, Washington, founded in 2019 to develop allogeneic, off-the-shelf universal donor cellular immunotherapies for cancer and infectious disease. The company's core technology is an exclusively licensed Notch-mediated stem cell expansion and directed differentiation platform, originally developed over more than 20 years of federally funded research at the Fred Hutchinson Cancer Research Center. The platform uses pooled umbilical cord blood-derived hematopoietic stem and progenitor cells (HSPCs) to generate multiple distinct cell types — including stem and progenitor cells, natural killer (NK) cells, and myeloid cells — that require no donor-patient HLA matching and can be cryopreserved for immediate, on-demand clinical use.

The company's lead clinical asset, dilanubicel, is a stem and progenitor cell therapy being evaluated in a global Phase 2 randomized controlled trial as an adjuvant to standard-of-care chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients; data from the study demonstrated a statistically significant increase in remission rates, and 27 of 28 participants survived at least one year without severe rejection symptoms. A second clinical asset, DVX201 (unmodified NK cells), has completed two Phase 1 trials in COVID-19 and relapsed/refractory AML/high-risk MDS and has been out-licensed to Coeptis Therapeutics for further development and commercialization. Preclinical programs include engineered CAR-NK cells and engineered monocyte/macrophage therapies targeting solid tumors. Dilanubicel received FDA Orphan Drug Designation in February 2024 and RMAT Designation in March 2024.

Deverra is pre-revenue, with a headcount of 11–50 employees, and generates income through one-time licensing transactions (e.g., the DVX201 out-license to Coeptis) and royalties, with future revenue expected from product sales upon regulatory approval. Distribution of investigational products occurs through regulated clinical trial sites in partnership with Fred Hutchinson Cancer Center, the University of Washington, Duke University, and Novant Health. The company is also positioned to license out additional NK and myeloid cell programs, and is actively hiring across research, manufacturing, and clinical functions.

Short descriptiontext

Deverra Therapeutics is a Seattle-based, clinical-stage biotechnology company developing allogeneic, off-the-shelf universal donor cellular immunotherapies for cancer and infectious disease using an exclusively licensed Notch-mediated stem cell expansion platform from Fred Hutchinson Cancer Research Center, with its lead asset dilanubicel in a global Phase 2 trial for acute myeloid leukemia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, cellular immunotherapy, NK cell therapy, stem cell therapy, biopharmaceutical development
Industry3 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cellular Immunotherapy
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharmaceutical product revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company developing allogeneic cell therapy products for cancer and infectious diseases. Revenue will be generated through product sales upon regulatory approval.

deverratx.com
2Licensing and partnership revenue
TypeLicensing Royalties
Description

DVX201 NK cell products have been out-licensed to Coeptis Therapeutics, generating licensing revenue. The company also holds exclusive license to its platform technology.

deverratx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Dilanubicel
Description

Stem and progenitor cell therapy derived from cord blood, intended for use as a non-engrafting adjuvant cell therapy with chemotherapy to enhance remission rates and improve overall survival in AML patients.

deverratx.com
+1 more record
Core offering1 text field

Deverra Therapeutics develops allogeneic, off-the-shelf universal donor cellular immunotherapies manufactured from pooled umbilical cord blood using its proprietary Notch-mediated stem cell expansion and directed differentiation platform. Its clinical pipeline includes the lead product dilanubicel (stem and progenitor cells for acute myeloid leukemia), DVX201 (NK cells out-licensed to Coeptis Therapeutics), and preclinical CAR-NK and engineered monocyte/macrophage therapies for hematologic malignancies and solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 27 of 28 participants (96.4%) survived at least one year without severe rejection symptoms in phase 2 clinical trial
+3 more records
Product overview1 text field

Deverra Therapeutics is a clinical stage biotechnology company developing allogeneic, off-the-shelf universal donor cellular immunotherapies built on a proprietary Notch-mediated stem cell expansion and directed differentiation platform licensed from the Fred Hutchinson Cancer Research Center. The platform generates multiple cell types including stem and progenitor cells (lead product: Dilanubicel), natural killer (NK) cells (DVX201, now licensed to Coeptis Therapeutics), and myeloid cells. The company also develops engineered variants including CAR-NK cells and engineered monocyte/macrophage therapies for hematologic malignancies and solid tumors. All products are universal donor (no HLA matching required) and cryopreserved for immediate on-demand use.

Product and service5 records
1Dilanubicel
CategoryStem and progenitor cell therapy
Description

Stem and progenitor cell therapy derived from pooled umbilical cord blood, designed as a non-engrafting adjuvant cell therapy to enhance remission rates and improve overall survival in Acute Myeloid Leukemia (AML) patients when combined with standard-of-care chemotherapy. Lead product; evaluated in a global Phase 2 randomized controlled trial in newly diagnosed AML.

2DVX201
CategoryNK cell therapy
Description

Unmodified natural killer (NK) cell product generated from cord blood HSPCs using the Notch-mediated differentiation platform, intended to fight cancer and viral infections. Safely dosed in two Phase 1 clinical trials and now out-licensed to Coeptis Therapeutics.

3CAR-NK Cells
CategoryEngineered CAR-NK cell therapy
Description

Engineered chimeric antigen receptor natural killer (CAR-NK) cell therapy designed to target specific cancers with enhanced potency. Preclinical/IND-enabling pipeline asset.

4Unmodified Myeloid Cells (Monocytes/Macrophages)
CategoryMyeloid cell therapy
Description

Unmodified monocytes and macrophages generated from cord blood HSPCs, designed to phagocytose abnormal cells, bacteria, and pathogens, and to activate and educate other immune cells by releasing cytokines and presenting antigens.

5Engineered Monocyte/Macrophage Cell Therapies
CategoryEngineered myeloid cell therapy
Description

Engineered monocyte and macrophage cell therapies designed for solid tumor treatment, intended to be used alone or in combination with other cell therapy products; may be engineered to secrete stimulatory cytokines to recruit additional immune cells and enhance killing of resistant solid tumor cells.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Deverra has an exclusive license to the proprietary Notch-mediated stem cell expansion and directed differentiation platform from Fred Hutchinson Cancer Research Center. The center has over 20 years of federally funded research in this technology. Researchers from Fred Hutch collaborated on the dilanubicel clinical trial published in Journal of Clinical Oncology.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

DVX201 NK cell product has been safely dosed in two Phase 1 clinical trials (DVX201-COV-01 for COVID-19 and DVX201-AML-01 for AML/MDS), now licensed to Coeptis Therapeutics for further development and commercialization. Deverra aims to license out additional NK and myeloid cell programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partner for DVX201-COV-01 Phase 1 study testing allogeneic NK cell therapy in subjects hospitalized for COVID-19.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial partner for DVX201-AML-01 study evaluating safety and efficacy of DVX201 NK cells in patients with relapsed/refractory AML or high-risk MDS.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial partner for dilanubicel study in acute myeloid leukemia.

6National Cord Blood Program (NCBP)
Strategic tierCoreTypeOthers
Description

Cord blood bank partner providing sustainable, healthy donor umbilical cord blood cells as starting material for Deverra's cell therapy platform.

deverratx.com
Strategic tierCoreTypeOthers
Description

Cord blood bank partner providing sustainable, healthy donor umbilical cord blood cells as starting material for Deverra's cell therapy platform.

Strategic tierMinorTypeOthers
Description

Research partner providing cord blood resources for research and development activities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Focused on allogeneic cell therapies for patients with hematologic malignancies, particularly AML. Comparable disease focus and allogeneic approach to engineered hematopoietic cells.

TypeDirect peer
Description

Focused on allogeneic, off-the-shelf NK cell therapies engineered with CARs for cancer, including AML. Closely aligned with Deverra's DVX201 and CAR-NK programs and shares the universal donor positioning.

TypeDirect peer
Description

Commercializes an FDA-approved cell therapy (Omisirge) for patients with hematologic malignancies undergoing umbilical cord blood transplantation. Direct overlap in cord blood-derived cell therapies for AML/transplant.

TypeDirect peer
Description

Uses placenta and cord blood-derived cells to develop off-the-shelf allogeneic cell therapies, including NK cell candidates for AML and other cancers. Highly comparable raw material and universal donor positioning to Deverra.

TypeDirect peer
Description

Clinical-stage biotech developing off-the-shelf, allogeneic NK and T cell therapies from a renewable iPSC platform. Directly comparable to Deverra in modality (universal donor cell therapy) and target indications including hematologic malignancies.

TypeDirect peer
Description

Clinical-stage company developing allogeneic CAR-T and CAR-NK cell therapies using CRISPR-based gene editing. Overlaps with Deverra in engineered, universal donor immune effector cell therapies for cancer.

TypeDirect peer
Description

Develops allogeneic, off-the-shelf NK cell therapies derived from induced pluripotent stem cells. Comparable modality (universal donor NK) and emerging pipeline in hematologic malignancies.

TypeBroad incumbent
Description

Pioneering allogeneic CAR-T therapies across multiple hematologic malignancies. A larger, broader incumbent in the allogeneic cell therapy space with overlapping clinical ambitions in B-cell malignancies and beyond.

TypeDirect peer
Description

Developing allogeneic, iPSC-derived immune cell therapies (NK and T cells) for hematologic and solid tumors. Comparable in platform philosophy (renewable, universal donor cell source) and oncology focus.

10Kiadis Pharma (a Sanofi company)
TypeBroad incumbent
Description

Acquired by Sanofi, developed allogeneic NK cell platforms (PM21 particles) for cancer and infectious diseases. Provides a benchmark for an NK platform that scaled via strategic acquisition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deverra Therapeutics

Cellular Immunotherapydeverratx.com

Deverra Therapeutics is a Seattle-based, clinical-stage biotechnology company developing allogeneic, off-the-shelf universal donor cellular immunotherapies for cancer and infectious disease using an exclusively licensed Notch-mediated stem cell expansion platform from Fred Hutchinson Cancer Research Center, with its lead asset dilanubicel in a global Phase 2 trial for acute myeloid leukemia.

What Deverra Therapeutics does

Deverra Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered in Seattle, Washington, founded in 2019 to develop allogeneic, off-the-shelf universal donor cellular immunotherapies for cancer and infectious disease. The company's core technology is an exclusively licensed Notch-mediated stem cell expansion and directed differentiation platform, originally developed over more than 20 years of federally funded research at the Fred Hutchinson Cancer Research Center. The platform uses pooled umbilical cord blood-derived hematopoietic stem and progenitor cells (HSPCs) to generate multiple distinct cell types — including stem and progenitor cells, natural killer (NK) cells, and myeloid cells — that require no donor-patient HLA matching and can be cryopreserved for immediate, on-demand clinical use.

The company's lead clinical asset, dilanubicel, is a stem and progenitor cell therapy being evaluated in a global Phase 2 randomized controlled trial as an adjuvant to standard-of-care chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients; data from the study demonstrated a statistically significant increase in remission rates, and 27 of 28 participants survived at least one year without severe rejection symptoms. A second clinical asset, DVX201 (unmodified NK cells), has completed two Phase 1 trials in COVID-19 and relapsed/refractory AML/high-risk MDS and has been out-licensed to Coeptis Therapeutics for further development and commercialization. Preclinical programs include engineered CAR-NK cells and engineered monocyte/macrophage therapies targeting solid tumors. Dilanubicel received FDA Orphan Drug Designation in February 2024 and RMAT Designation in March 2024.

Deverra is pre-revenue, with a headcount of 11–50 employees, and generates income through one-time licensing transactions (e.g., the DVX201 out-license to Coeptis) and royalties, with future revenue expected from product sales upon regulatory approval. Distribution of investigational products occurs through regulated clinical trial sites in partnership with Fred Hutchinson Cancer Center, the University of Washington, Duke University, and Novant Health. The company is also positioned to license out additional NK and myeloid cell programs, and is actively hiring across research, manufacturing, and clinical functions.

Deverra Therapeutics firmographics

Firmographics
Name
Deverra Therapeutics
Legal name
Deverra Therapeutics, Inc.
Website
https://deverratx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Deverra Therapeutics is a Seattle-based, clinical-stage biotechnology company developing allogeneic, off-the-shelf universal donor cellular immunotherapies for cancer and infectious disease using an exclusively licensed Notch-mediated stem cell expansion platform from Fred Hutchinson Cancer Research Center, with its lead asset dilanubicel in a global Phase 2 trial for acute myeloid leukemia.
Ownership category
akta.pro rank

Deverra Therapeutics industry classification

Industry
Product category
Cellular Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Allogeneic cell therapy
  • Cellular immunotherapy
  • NK cell therapy
  • Stem cell therapy
  • Biopharmaceutical development

Where Deverra Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Deverra Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Biopharmaceutical product revenue: Pre-revenue clinical-stage company developing allogeneic cell therapy products for cancer and infectious diseases. Revenue will be generated through product sales upon regulatory approval.
  2. Licensing and partnership revenue: DVX201 NK cell products have been out-licensed to Coeptis Therapeutics, generating licensing revenue. The company also holds exclusive license to its platform technology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Deverra Therapeutics product offering

Product offering

Core offering

Deverra Therapeutics develops allogeneic, off-the-shelf universal donor cellular immunotherapies manufactured from pooled umbilical cord blood using its proprietary Notch-mediated stem cell expansion and directed differentiation platform. Its clinical pipeline includes the lead product dilanubicel (stem and progenitor cells for acute myeloid leukemia), DVX201 (NK cells out-licensed to Coeptis Therapeutics), and preclinical CAR-NK and engineered monocyte/macrophage therapies for hematologic malignancies and solid tumors.

Product overview

Deverra Therapeutics is a clinical stage biotechnology company developing allogeneic, off-the-shelf universal donor cellular immunotherapies built on a proprietary Notch-mediated stem cell expansion and directed differentiation platform licensed from the Fred Hutchinson Cancer Research Center. The platform generates multiple cell types including stem and progenitor cells (lead product: Dilanubicel), natural killer (NK) cells (DVX201, now licensed to Coeptis Therapeutics), and myeloid cells. The company also develops engineered variants including CAR-NK cells and engineered monocyte/macrophage therapies for hematologic malignancies and solid tumors. All products are universal donor (no HLA matching required) and cryopreserved for immediate on-demand use.

Differentiator

Problem solved

Functional benefit

Brands

  • Dilanubicel: Stem and progenitor cell therapy derived from cord blood, intended for use as a non-engrafting adjuvant cell therapy with chemotherapy to enhance remission rates and improve overall survival in AML patients.
  • DVX201

Products and services

  • Dilanubicel Stem and progenitor cell therapy derived from pooled umbilical cord blood, designed as a non-engrafting adjuvant cell therapy to enhance remission rates and improve overall survival in Acute Myeloid Leukemia (AML) patients when combined with standard-of-care chemotherapy. Lead product; evaluated in a global Phase 2 randomized controlled trial in newly diagnosed AML.
  • DVX201 Unmodified natural killer (NK) cell product generated from cord blood HSPCs using the Notch-mediated differentiation platform, intended to fight cancer and viral infections. Safely dosed in two Phase 1 clinical trials and now out-licensed to Coeptis Therapeutics.
  • CAR-NK Cells Engineered chimeric antigen receptor natural killer (CAR-NK) cell therapy designed to target specific cancers with enhanced potency. Preclinical/IND-enabling pipeline asset.
  • Unmodified Myeloid Cells (Monocytes/Macrophages) Unmodified monocytes and macrophages generated from cord blood HSPCs, designed to phagocytose abnormal cells, bacteria, and pathogens, and to activate and educate other immune cells by releasing cytokines and presenting antigens.
  • Engineered Monocyte/Macrophage Cell Therapies Engineered monocyte and macrophage cell therapies designed for solid tumor treatment, intended to be used alone or in combination with other cell therapy products; may be engineered to secrete stimulatory cytokines to recruit additional immune cells and enhance killing of resistant solid tumor cells.

Quantifiable outcome

  • 27 of 28 participants (96.4%) survived at least one year without severe rejection symptoms in phase 2 clinical trial
  • +3 more outcomes

Companies that use Deverra Therapeutics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Deverra Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Deverra Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Fred Hutchinson Cancer Research CentercoreStrategic or Co-development PartnerDeverra has an exclusive license to the proprietary Notch-mediated stem cell expansion and directed differentiation platform from Fred Hutchinson Cancer Research Center. The center has over 20 years of federally funded research in this technology. Researchers from Fred Hutch collaborated on the dilanubicel clinical trial published in Journal of Clinical Oncology.
  • Coeptis TherapeuticscoreChannel Partner/ Reseller/ DistributorDVX201 NK cell product has been safely dosed in two Phase 1 clinical trials (DVX201-COV-01 for COVID-19 and DVX201-AML-01 for AML/MDS), now licensed to Coeptis Therapeutics for further development and commercialization. Deverra aims to license out additional NK and myeloid cell programs.
  • University of WashingtoncoreStrategic or Co-development PartnerClinical trial partner for DVX201-COV-01 Phase 1 study testing allogeneic NK cell therapy in subjects hospitalized for COVID-19.
  • Novant HealthminorStrategic or Co-development PartnerClinical trial partner for DVX201-AML-01 study evaluating safety and efficacy of DVX201 NK cells in patients with relapsed/refractory AML or high-risk MDS.
  • Duke UniversityminorStrategic or Co-development PartnerClinical trial partner for dilanubicel study in acute myeloid leukemia.
  • National Cord Blood Program (NCBP)coreOthersCord blood bank partner providing sustainable, healthy donor umbilical cord blood cells as starting material for Deverra's cell therapy platform.
  • CariCord (CCB)coreOthersCord blood bank partner providing sustainable, healthy donor umbilical cord blood cells as starting material for Deverra's cell therapy platform.
  • New York Blood Bank (NYBB)minorOthersResearch partner providing cord blood resources for research and development activities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Deverra Therapeutics competitors and assessment

Company assessment

Direct peers

  • VOR BioPharma: Focused on allogeneic cell therapies for patients with hematologic malignancies, particularly AML. Comparable disease focus and allogeneic approach to engineered hematopoietic cells.
  • Nkarta Therapeutics: Focused on allogeneic, off-the-shelf NK cell therapies engineered with CARs for cancer, including AML. Closely aligned with Deverra's DVX201 and CAR-NK programs and shares the universal donor positioning.
  • Gamida Cell: Commercializes an FDA-approved cell therapy (Omisirge) for patients with hematologic malignancies undergoing umbilical cord blood transplantation. Direct overlap in cord blood-derived cell therapies for AML/transplant.
  • Celularity: Uses placenta and cord blood-derived cells to develop off-the-shelf allogeneic cell therapies, including NK cell candidates for AML and other cancers. Highly comparable raw material and universal donor positioning to Deverra.
  • Fate Therapeutics: Clinical-stage biotech developing off-the-shelf, allogeneic NK and T cell therapies from a renewable iPSC platform. Directly comparable to Deverra in modality (universal donor cell therapy) and target indications including hematologic malignancies.
  • Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T and CAR-NK cell therapies using CRISPR-based gene editing. Overlaps with Deverra in engineered, universal donor immune effector cell therapies for cancer.
  • Shoreline Biosciences: Develops allogeneic, off-the-shelf NK cell therapies derived from induced pluripotent stem cells. Comparable modality (universal donor NK) and emerging pipeline in hematologic malignancies.
  • Century Therapeutics: Developing allogeneic, iPSC-derived immune cell therapies (NK and T cells) for hematologic and solid tumors. Comparable in platform philosophy (renewable, universal donor cell source) and oncology focus.

Broad incumbents

  • Allogene Therapeutics: Pioneering allogeneic CAR-T therapies across multiple hematologic malignancies. A larger, broader incumbent in the allogeneic cell therapy space with overlapping clinical ambitions in B-cell malignancies and beyond.
  • Kiadis Pharma (a Sanofi company): Acquired by Sanofi, developed allogeneic NK cell platforms (PM21 particles) for cancer and infectious diseases. Provides a benchmark for an NK platform that scaled via strategic acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Deverra Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deverra Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Deverra Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deverra Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deverra Therapeutics

What does Deverra Therapeutics do?

Deverra Therapeutics develops allogeneic, off-the-shelf universal donor cellular immunotherapies manufactured from pooled umbilical cord blood using its proprietary Notch-mediated stem cell expansion and directed differentiation platform. Its clinical pipeline includes the lead product dilanubicel (stem and progenitor cells for acute myeloid leukemia), DVX201 (NK cells out-licensed to Coeptis Therapeutics), and preclinical CAR-NK and engineered monocyte/macrophage therapies for hematologic malignancies and solid tumors.

Is Deverra Therapeutics a public or private company?

Deverra Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deverra Therapeutics founded?

Deverra Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Deverra Therapeutics based?

Deverra Therapeutics is headquartered in Seattle, United States, in the North America region.

How does Deverra Therapeutics make money?

Two revenue lines are on record. Biopharmaceutical product revenue is the primary driver. The others are licensing and partnership revenue.

Who are Deverra Therapeutics's main competitors?

Direct peers on record are VOR BioPharma, Nkarta Therapeutics, Gamida Cell, Celularity, Fate Therapeutics, Caribou Biosciences, Shoreline Biosciences and Century Therapeutics. Broad incumbents are Allogene Therapeutics and Kiadis Pharma (a Sanofi company).

Does Deverra Therapeutics have an API?

No public API is recorded for Deverra Therapeutics.

What industry is Deverra Therapeutics in?

Deverra Therapeutics's product category is Cellular Immunotherapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
UsnewsPooled Umbilical Cord Blood Boosts Stem Cell Transplant Success, Trial FindsA clinical trial published in the Journal of Clinical Oncology found that pooling umbilical cord blood from multiple donors significantly improved stem cell transplant outcomes for leukemia patients, with 27 of 28 participants surviving at least one year without severe rejection symptoms. The new stem cell product, dilanubicel (developed by Deverra Therapeutics), combines blood stem cells from six to eight different cord blood units that are nurtured and expanded in a laboratory before infusion. Researchers from the Fred Hutchinson Cancer Center in Seattle are now seeking additional funding for larger follow-up clinical trials to confirm these findings.PR NewswireCoeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency UseCoeptis Therapeutics Holdings, Inc. has expanded its existing license agreement with Deverra Therapeutics Inc. to include the use of its allogeneic natural killer (NK) cell technology for pandemic preparedness, emergency use situations, and treatment of illnesses arising from pandemics or acts of terror or war.StartEngineInvest in Deverra TherapeuticsDeverra Therapeutics is seeking additional funding to conduct a final clinical trial for its lead asset, Dilanubicel, aiming for FDA approval in the treatment of Acute Myeloid Leukemia. The company previously raised $20.4 million and highlights a phase 2 trial result showing significantly improved remission rates compared to standard chemotherapy. This capital raise supports the company's goal to commercialize its off-the-shelf immune cell therapy technology.PR NewswireCoeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024Coeptis Therapeutics Holdings, Inc. has been selected to give an oral presentation on its first-in-class universal allogeneic SNAP-CAR NK cell therapy at the International Society for Cell & Gene Therapy 2024 conference in Vancouver, Canada. The SNAP-CAR platform technology, developed in collaboration with the University of Pittsburgh and Deverra Therapeutics, enables engineered NK cells to target multiple tumor antigens through a self-labeling reaction, potentially offering a safer and more cost-effective alternative to autologous CAR T-cell therapies. The presentation is scheduled for May 30, 2024, as part of the five-day conference bringing together leading researchers and industry experts in cell and gene therapy.PR NewswireCoeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingCoeptis Therapeutics Holdings, Inc. announced that its abstract on SNAP-CAR NK cell development will be featured as a poster presentation at the 2024 American Society of Gene and Cell Therapy Annual Meeting in Baltimore, MD from May 7-11, 2024, with Dr. Carrie Stoltzman from Deverra Therapeutics presenting on behalf of the company. The SNAP-CAR NK platform is designed to target multiple antigens and has the potential to address a wide range of cancers using a first-in-class universal, antigen-agnostic targeted cell therapy approach without requiring HLA matching. The company's CEO described this presentation as a significant milestone toward advancing the technology toward first-in-human clinical trials.PR NewswireCoeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesCoeptis Therapeutics announced that Dan Yerace, its Director and Vice President of Operations, will participate in a panel discussion titled "Ambitious Innovation: Emerging Cell and Gene Therapies" at the BioFlorida Conference on October 12, 2023. The company is developing innovative cell therapy platforms for cancer, including assets licensed from Deverra Therapeutics and technologies developed with partners like VyGen-Bio and the Karolinska Institutet.American City Business JournalsCoeptis Therapeutics reaches clinical-stage following license acquisitionCoeptis Therapeutics, based in Wexford, acquired a license from Deverra Therapeutics for $570,000 in cash and stock. The deal expands Coeptis's portfolio and could lead to accelerated product development.PR NewswireCoeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsCoeptis Therapeutics Holdings, Inc. has completed an exclusive license for Deverra Therapeutics' proprietary allogeneic stem cell expansion and directed differentiation platform, acquiring rights to two Investigational New Drug applications and two Phase 1 clinical stage assets targeting NK cell therapies for hematologic malignancies and viral infections. Coeptis paid approximately $570,000 in cash and issued 4,000,000 shares of common stock to Deverra as consideration for the transaction. The deal transitions Coeptis into a clinical-stage biopharmaceutical company with an expanded pipeline of cell therapy candidates leveraging off-the-shelf NK and monocyte/macrophage technologies.American City Business JournalsCoeptis Therapeutics to acquire cell therapies from Deverra TherapeuticsCoeptis Therapeutics announced plans to acquire a cell therapy in phase one clinical trials, causing its shares to rise 10% on Tuesday. The company is based in Wexford.PR NewswireCleveland Cord Blood Center and Deverra Therapeutics Announce AgreementDeverra Therapeutics entered a manufacturing service agreement with Cleveland Cell Therapy Incubator, a subsidiary of the Cleveland Cord Blood Center, to produce clinical-grade expanded cord blood progenitors and immune cells. The agreement supports Deverra's mid-stage clinical development programs, with production at CCTI's Cleveland facility. The collaboration extends from prior supply programs since 2018.